Alnylam Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Alnylam Pharmaceuticals's earnings have been declining at an average annual rate of -0.6%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 45.2% per year.
Key information
-0.6%
Earnings growth rate
3.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 45.2% |
Return on equity | n/a |
Net Margin | -24.1% |
Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking
Mar 19Is Alnylam's HELIOS-B Delay A Red Flag?
Mar 10Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think
Feb 18Alnylam's Huge Opportunity
Jan 12Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues
Dec 18Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares
Jun 23Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
Oct 25Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo
Oct 07Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market
Sep 26Alnylam RNAi therapy for rare protein disorder gets EU approval
Sep 20Alnylam to offer $900M convertible senior notes
Sep 12Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy
Aug 29Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity
Aug 18APOLLO Hits A Bullseye, And Alnylam Logs Another Major Clinical Win
Aug 04Alnylam to target abdominal obesity after research data on gene mutation
Jul 27Alnylam Pharmaceuticals Heading Toward A Key Trial Read-Out
Jul 19Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?
Jun 21Revenue & Expenses BreakdownBeta
How Alnylam Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,828 | -440 | 796 | 1,004 |
30 Sep 23 | 1,724 | -510 | 808 | 994 |
30 Jun 23 | 1,237 | -1,064 | 845 | 987 |
31 Mar 23 | 1,143 | -1,065 | 800 | 944 |
31 Dec 22 | 1,037 | -1,131 | 771 | 883 |
30 Sep 22 | 961 | -1,182 | 747 | 850 |
30 Jun 22 | 884 | -981 | 653 | 799 |
31 Mar 22 | 880 | -893 | 628 | 776 |
31 Dec 21 | 844 | -853 | 621 | 792 |
30 Sep 21 | 749 | -838 | 619 | 713 |
30 Jun 21 | 688 | -887 | 662 | 662 |
31 Mar 21 | 571 | -876 | 663 | 617 |
31 Dec 20 | 493 | -858 | 588 | 655 |
30 Sep 20 | 401 | -891 | 646 | 620 |
30 Jun 20 | 345 | -846 | 594 | 624 |
31 Mar 20 | 286 | -886 | 574 | 637 |
31 Dec 19 | 220 | -886 | 534 | 600 |
30 Sep 19 | 169 | -821 | 482 | 534 |
30 Jun 19 | 101 | -858 | 477 | 515 |
31 Mar 19 | 86 | -802 | 446 | 491 |
31 Dec 18 | 75 | -761 | 425 | 463 |
30 Sep 18 | 92 | -692 | 379 | 454 |
30 Jun 18 | 107 | -570 | 306 | 414 |
31 Mar 18 | 93 | -525 | 264 | 370 |
31 Dec 17 | 90 | -491 | 230 | 360 |
30 Sep 17 | 69 | -462 | 191 | 346 |
30 Jun 17 | 66 | -443 | 166 | 349 |
31 Mar 17 | 59 | -414 | 137 | 342 |
31 Dec 16 | 47 | -410 | 119 | 352 |
30 Sep 16 | 37 | -388 | 106 | 333 |
30 Jun 16 | 30 | -361 | 98 | 305 |
31 Mar 16 | 30 | -342 | 93 | 291 |
31 Dec 15 | 41 | -290 | 82 | 255 |
30 Sep 15 | 58 | -221 | 78 | 229 |
30 Jun 15 | 62 | -188 | 71 | 208 |
31 Mar 15 | 61 | -160 | 67 | 186 |
31 Dec 14 | 51 | -360 | 63 | 172 |
30 Sep 14 | 37 | -371 | 56 | 150 |
30 Jun 14 | 35 | -357 | 52 | 139 |
31 Mar 14 | 37 | -331 | 45 | 119 |
31 Dec 13 | 47 | -89 | 41 | 99 |
30 Sep 13 | 45 | -119 | 43 | 89 |
30 Jun 13 | 53 | -109 | 48 | 77 |
Quality Earnings: ALNY is currently unprofitable.
Growing Profit Margin: ALNY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALNY is unprofitable, and losses have increased over the past 5 years at a rate of 0.6% per year.
Accelerating Growth: Unable to compare ALNY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALNY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: ALNY's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.